
Guggenheim has raised the stock price target for Inventiva due to a positive trial outlook.
No additional details are provided about the trial or the new target price.
Key Takeaways
Center
Coverage blindspot: Reporting on this development is currently concentrated in other segments of the media landscape.
Coverage blindspot: Reporting on this development is currently concentrated in other segments of the media landscape.
Get every side of the week's biggest story in your inbox.
Impact on investors and the biotech industry
No attributed perspective yet — we only show quotes grounded in analysis.
Evaluated across 1 reporting source (0% Left · 100% Center · 0% Right)
Historical editorial baseline for Investing.com
Multi-factor accuracy index for Investing.com and related desks based on verifiable sourcing and editorial standards.
Factuality: High 100%
Ownership: Investing.com (Corporate)
Public conversation related to this story
Loading comments…